Dr. Hanfang Jiang 姜晗昉
Chief Physician
Department of Medical Oncology for Breast Cancer, Peking University Cancer Hospital, Beijing
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Systemic chemotherapy, targeted therapy, endocrine therapy, and NGS-guided precision treatment for early-stage and metastatic breast cancer, including hormone receptor-positive, triple-negative, and HER2-positive subtypes.
Dr. Jiang is a Chief Physician in the Department of Medical Oncology for Breast Tumors at Peking University Cancer Hospital and holds a medical doctorate in oncology from Peking University. Dr. Jiang served as a visiting scholar at the UCSF Helen Diller Family Comprehensive Cancer Center from August 2014 to September 2015.
Professional roles
- Member, Breast Cancer Professional Committee, China Anti-Cancer Association
- Standing Committee Member, Tumor Clinical Research Professional Committee, China Medicine Education Association
- Standing Committee Member, Breast Professional Committee, China Women Doctors Association
- Member, Breast Cancer Precision Targeted Diagnosis and Treatment Professional Committee, Beijing Cancer Prevention and Control Society
Name order: in Chinese the family name comes first (Jiang Hanfang). Papers usually list the name as Hanfang Jiang or Jiang H.
Selected publications
52 papers on PubMed matched by name and affiliation; 7 as first or senior author since 2016. Most recent first- or senior-author papers:
- Cancer Med, 2024 (first author): Abemaciclib plus endocrine therapy versus chemotherapy after progression on prior palbociclib in HR+/HER2- metastatic breast cancer: A single center real-world study in China. PubMed 38770648
- Breast Cancer Res Treat, 2023 (first author): Pegylated liposomal doxorubicin (Duomeisu(®)) monotherapy in patients with HER2-negative metastatic breast cancer heavily pretreated with anthracycline and taxanes: a single-arm, phase II study. PubMed 36877215
- Eur J Cancer, 2022 (first author): Proxalutamide in patients with AR-positive metastatic breast cancer: Results from an open-label multicentre phase Ib study and biomarker analysis. PubMed 36182805
- Cancer Med, 2021 (first author): Bilateral breast cancer in China: A 10-year single-center retrospective study (2006-2016). PubMed 34346560
- BMC Cancer, 2021 (first author): Prognostic values of tumoral MMP2 and MMP9 overexpression in breast cancer: a systematic review and meta-analysis. PubMed 33568081
- J Cancer, 2020 (senior author): Efficacy and Safety of Fulvestrant 500mg in Hormone-receptor Positive Human Epidermal Receptor 2 Negative Advanced Breast Cancer: A Real-world Study in China. PubMed 33046982
- Medicine (Baltimore), 2018 (senior author): Long term use of bevacizumab in the treatment of triple negative breast cancer with giant tumor in chest wall: A case report. PubMed 30508942
- Ther Adv Med Oncol, 2015 (first author): Human epidermal growth factor receptor 2 positive (HER2+) metastatic breast cancer: how the latest results are improving therapeutic options. PubMed 26557900
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion